IRADIMED CORPORATION
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $83.8M | $73.2M | $65.6M | $53.3M | $41.8M | $31.7M | $38.5M | $30.4M |
| Cost of Revenue | $19.5M | $16.9M | $15.4M | $12.0M | $9.8M | $8.1M | $8.8M | $7.2M |
| Gross Profit | $64.3M | $56.4M | $50.2M | $41.3M | $32.0M | $23.6M | $29.7M | $23.2M |
| Gross Margin | 76.7% | 76.9% | 76.5% | 77.4% | 76.6% | 74.3% | 77.1% | 76.3% |
| Operating Expenses | ||||||||
| Research & Development | $3.0M | $2.8M | $2.9M | $2.3M | $1.9M | $1.9M | $1.4M | $1.5M |
| SG&A Expense | $17.8M | $15.9M | $15.1M | $10.7M | $9.8M | $12.3M | $10.5M | $8.7M |
| Operating Income | $26.1M | $22.0M | $20.0M | $15.6M | $9.8M | $-756.1K | $8.6M | $6.0M |
| Operating Margin | 31.2% | 30.0% | 30.6% | 29.3% | 23.5% | -2.4% | 22.5% | 19.7% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $28.4M | $24.3M | $21.7M | $16.2M | $9.8M | $-616.9K | $9.0M | $6.2M |
| Income Tax Expense | $5.9M | $5.0M | $4.5M | $3.4M | $510.8K | $-2.0M | $-587.6K | $-106.1K |
| Net Income | $22.5M | $19.2M | $17.2M | $12.8M | $9.3M | $1.4M | $9.6M | $6.3M |
| Net Margin | 26.8% | 26.3% | 26.2% | 24.1% | 22.3% | 4.3% | 25.0% | 20.7% |
| EPS (Basic) | $1.77 | $1.52 | $1.36 | $1.02 | $0.76 | $0.11 | $0.85 | $0.59 |
| EPS (Diluted) | $1.75 | $1.50 | $1.35 | $1.02 | $0.74 | $0.11 | $0.78 | $0.52 |
| Shares Outstanding (Basic) | 12.7M | 12.7M | 12.6M | 12.6M | 12.3M | 12.1M | 11.3M | 10.8M |
| Shares Outstanding (Diluted) | 12.9M | 12.8M | 12.7M | 12.6M | 12.6M | 12.4M | 12.3M | 12.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |